These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

641 related articles for article (PubMed ID: 20168090)

  • 1. Neutralizing epitopes of the SARS-CoV S-protein cluster independent of repertoire, antigen structure or mAb technology.
    Berry JD; Hay K; Rini JM; Yu M; Wang L; Plummer FA; Corbett CR; Andonov A
    MAbs; 2010; 2(1):53-66. PubMed ID: 20168090
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies.
    He Y; Lu H; Siddiqui P; Zhou Y; Jiang S
    J Immunol; 2005 Apr; 174(8):4908-15. PubMed ID: 15814718
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Identification and characterization of novel neutralizing epitopes in the receptor-binding domain of SARS-CoV spike protein: revealing the critical antigenic determinants in inactivated SARS-CoV vaccine.
    He Y; Li J; Du L; Yan X; Hu G; Zhou Y; Jiang S
    Vaccine; 2006 Jun; 24(26):5498-508. PubMed ID: 16725238
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Human monoclonal antibody combination against SARS coronavirus: synergy and coverage of escape mutants.
    ter Meulen J; van den Brink EN; Poon LL; Marissen WE; Leung CS; Cox F; Cheung CY; Bakker AQ; Bogaards JA; van Deventer E; Preiser W; Doerr HW; Chow VT; de Kruif J; Peiris JS; Goudsmit J
    PLoS Med; 2006 Jul; 3(7):e237. PubMed ID: 16796401
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antigenic and immunogenic characterization of recombinant baculovirus-expressed severe acute respiratory syndrome coronavirus spike protein: implication for vaccine design.
    He Y; Li J; Heck S; Lustigman S; Jiang S
    J Virol; 2006 Jun; 80(12):5757-67. PubMed ID: 16731915
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
    He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
    Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identifying epitopes responsible for neutralizing antibody and DC-SIGN binding on the spike glycoprotein of the severe acute respiratory syndrome coronavirus.
    Shih YP; Chen CY; Liu SJ; Chen KH; Lee YM; Chao YC; Chen YM
    J Virol; 2006 Nov; 80(21):10315-24. PubMed ID: 17041212
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular and biological characterization of human monoclonal antibodies binding to the spike and nucleocapsid proteins of severe acute respiratory syndrome coronavirus.
    van den Brink EN; Ter Meulen J; Cox F; Jongeneelen MA; Thijsse A; Throsby M; Marissen WE; Rood PM; Bakker AB; Gelderblom HR; Martina BE; Osterhaus AD; Preiser W; Doerr HW; de Kruif J; Goudsmit J
    J Virol; 2005 Feb; 79(3):1635-44. PubMed ID: 15650189
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cross-neutralization of human and palm civet severe acute respiratory syndrome coronaviruses by antibodies targeting the receptor-binding domain of spike protein.
    He Y; Li J; Li W; Lustigman S; Farzan M; Jiang S
    J Immunol; 2006 May; 176(10):6085-92. PubMed ID: 16670317
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice.
    Greenough TC; Babcock GJ; Roberts A; Hernandez HJ; Thomas WD; Coccia JA; Graziano RF; Srinivasan M; Lowy I; Finberg RW; Subbarao K; Vogel L; Somasundaran M; Luzuriaga K; Sullivan JL; Ambrosino DM
    J Infect Dis; 2005 Feb; 191(4):507-14. PubMed ID: 15655773
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A single amino acid substitution (R441A) in the receptor-binding domain of SARS coronavirus spike protein disrupts the antigenic structure and binding activity.
    He Y; Li J; Jiang S
    Biochem Biophys Res Commun; 2006 May; 344(1):106-13. PubMed ID: 16615996
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antibody-mediated synergy and interference in the neutralization of SARS-CoV at an epitope cluster on the spike protein.
    Zhong L; Haynes L; Struble EB; Tamin A; Virata-Theimer ML; Zhang P
    Biochem Biophys Res Commun; 2009 Dec; 390(3):1056-60. PubMed ID: 19861118
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antibody binding site mapping of SARS-CoV spike protein receptor-binding domain by a combination of yeast surface display and phage peptide library screening.
    Zhang X; Wang J; Wen K; Mou Z; Zou L; Che X; Ni B; Wu Y
    Viral Immunol; 2009 Dec; 22(6):407-15. PubMed ID: 19951177
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Structural insights into immune recognition of the severe acute respiratory syndrome coronavirus S protein receptor binding domain.
    Pak JE; Sharon C; Satkunarajah M; Auperin TC; Cameron CM; Kelvin DJ; Seetharaman J; Cochrane A; Plummer FA; Berry JD; Rini JM
    J Mol Biol; 2009 May; 388(4):815-23. PubMed ID: 19324051
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of an antigenic determinant on the S2 domain of the severe acute respiratory syndrome coronavirus spike glycoprotein capable of inducing neutralizing antibodies.
    Zhang H; Wang G; Li J; Nie Y; Shi X; Lian G; Wang W; Yin X; Zhao Y; Qu X; Ding M; Deng H
    J Virol; 2004 Jul; 78(13):6938-45. PubMed ID: 15194770
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of neutralizing monoclonal antibodies recognizing a 15-residues epitope on the spike protein HR2 region of severe acute respiratory syndrome coronavirus (SARS-CoV).
    Lai SC; Chong PC; Yeh CT; Liu LS; Jan JT; Chi HY; Liu HW; Chen A; Wang YC
    J Biomed Sci; 2005 Oct; 12(5):711-27. PubMed ID: 16132115
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting SARS-CoV2 Spike Protein Receptor Binding Domain by Therapeutic Antibodies.
    Hussain A; Hasan A; Nejadi Babadaei MM; Bloukh SH; Chowdhury MEH; Sharifi M; Haghighat S; Falahati M
    Biomed Pharmacother; 2020 Oct; 130():110559. PubMed ID: 32768882
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structural basis for potent cross-neutralizing human monoclonal antibody protection against lethal human and zoonotic severe acute respiratory syndrome coronavirus challenge.
    Rockx B; Corti D; Donaldson E; Sheahan T; Stadler K; Lanzavecchia A; Baric R
    J Virol; 2008 Apr; 82(7):3220-35. PubMed ID: 18199635
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Priming with SARS CoV S DNA and boosting with SARS CoV S epitopes specific for CD4+ and CD8+ T cells promote cellular immune responses.
    Huang J; Cao Y; Du J; Bu X; Ma R; Wu C
    Vaccine; 2007 Sep; 25(39-40):6981-91. PubMed ID: 17709158
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An exposed domain in the severe acute respiratory syndrome coronavirus spike protein induces neutralizing antibodies.
    Zhou T; Wang H; Luo D; Rowe T; Wang Z; Hogan RJ; Qiu S; Bunzel RJ; Huang G; Mishra V; Voss TG; Kimberly R; Luo M
    J Virol; 2004 Jul; 78(13):7217-26. PubMed ID: 15194798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 33.